U.S. markets open in 8 hours 19 minutes
  • S&P Futures

    3,931.00
    +8.50 (+0.22%)
     
  • Dow Futures

    32,007.00
    +91.00 (+0.29%)
     
  • Nasdaq Futures

    13,338.00
    +36.00 (+0.27%)
     
  • Russell 2000 Futures

    2,299.90
    +14.80 (+0.65%)
     
  • Crude Oil

    63.40
    +0.18 (+0.28%)
     
  • Gold

    1,799.40
    +1.50 (+0.08%)
     
  • Silver

    28.24
    +0.38 (+1.35%)
     
  • EUR/USD

    1.2183
    +0.0015 (+0.12%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4155
    +0.0013 (+0.09%)
     
  • USD/JPY

    105.9090
    +0.0270 (+0.03%)
     
  • BTC-USD

    50,406.90
    -501.27 (-0.98%)
     
  • CMC Crypto 200

    1,006.63
    +11.97 (+1.20%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,139.22
    +467.52 (+1.58%)
     

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / January 23, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ:NLTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Neoleukin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On January 8, 2021, Neoleukin announced that "on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201." Neoleukin disclosed that "[t]he FDA has informed Neoleukin that it needs to develop a new assay that more precisely measures the amount of protein being administered and demonstrate with this assay that dose and administration procedures will accurately deliver the intended dose of NL-201" and that "[t]he FDA also had additional requests not related to the clinical hold to be addressed by amendment of the IND."

On this news, Neoleukin's stock price fell $1.73 per share, or 10.96%, to close at $14.05 per share on January 8, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP



View source version on accesswire.com:
https://www.accesswire.com/625595/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Neoleukin-Therapeutics-Inc--NLTX